The purpose of the study is to assess how well the STN1010904 eye drops work in improving vision and the health of the cornea in people with Fuchs Endothelial Corneal Dystrophy. Participants in the study will use the eye drops twice a day. The study will last for about 18 months, during which time participants will have regular check-ups to monitor their vision and eye health. These check-ups will include tests to measure vision clarity and sensitivity to light, as well as examinations of the eye using special equipment.

Throughout the study, the safety of the STN1010904 eye drops will be closely monitored. This will involve checking for any side effects and conducting various eye examinations, such as looking at the eye with a special microscope and measuring the pressure inside the eye. The study aims to provide valuable information on whether these eye drops can be a beneficial treatment option for people with Fuchs Endothelial Corneal Dystrophy.

The purpose of the study is to see how quickly vision improves after using the Ripasudil eye drops compared to a placebo, which is a substance with no active medication. Participants will be randomly assigned to receive either the Ripasudil eye drops or the placebo. The study will last for a total of 12 weeks, with an additional two-week period where the dose is gradually reduced, followed by a 38-week follow-up phase to monitor long-term effects.

Throughout the study, participants will have their vision checked regularly to see how well they can see letters on a chart, which is a common way to measure vision improvement. The study aims to determine if the eye drops can help achieve a significant improvement in vision during the first 12 weeks after the procedure. Participants will also be monitored for any changes in the cornea and any side effects from the treatment.

The purpose of the study is to determine how well Ripasudil works in improving vision in patients with Fuchs Dystrophy after their surgery. Participants in the study will be randomly assigned to receive either the Ripasudil eye drops or a placebo, which looks like the real medication but does not contain the active ingredient. The study will last for a total of 12 weeks, during which time the participants will gradually reduce their dosage over a two-week period. After this, there will be a follow-up phase lasting 38 weeks to monitor the participants’ progress.

Throughout the study, the main focus will be on how quickly participants’ vision improves, measured by their ability to read letters on an eye chart. The study will also look at other factors, such as changes in the health of the cornea. This research aims to provide valuable information on whether Ripasudil can be a beneficial treatment option for those with Fuchs Dystrophy undergoing cataract surgery and descemetorhexis.

The purpose of the study is to compare the effects of these medication regimens on eye inflammation and a condition called cystoid macular edema, which can affect vision. Participants in the study will be randomly assigned to one of the two treatment groups. The study will monitor changes in the thickness of the central part of the retina, known as the macula, and the presence of any fluid-filled cysts in this area. The study will also look at other factors such as eye pressure and visual clarity over a period of time.

Participants will receive either the combination of NEVANAC and Spersadex or only Spersadex for a set period after their surgery. The study aims to provide insights into which treatment regimen is more effective in managing inflammation and preventing cystoid macular edema following corneal endothelial transplantation.